---
title: "Clofazimine - Pyoderma Gangrenosum"
sidebar: mydoc_sidebar
permalink: db00845-mesh-d017511-1.html
toc: false 
---


Path ID: `DB00845_MESH_D017511_1`
{% include image.html url="images/db00845-mesh-d017511-1.png" file="db00845-mesh-d017511-1.png" alt="db00845-mesh-d017511-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| MESH:D002991 | clofazimine | Drug |
| UniProt:P22001 | Potassium voltage-gated channel subfamily A member 3 | Protein |
| GO:0005244 | voltage-gated ion channel activity | MolecularActivity |
| REACT:R-HSA-2025928 | Calcineurin activates NFAT | Pathway |
| GO:0006954 | inflammatory response | BiologicalProcess |
| MESH:D017511 | Pyoderma gangrenosum | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Clofazimine | DECREASES ACTIVITY OF | Potassium Voltage-Gated Channel Subfamily A Member 3 |
| Potassium Voltage-Gated Channel Subfamily A Member 3 | POSITIVELY REGULATES | Voltage-Gated Ion Channel Activity |
| Voltage-Gated Ion Channel Activity | POSITIVELY REGULATES | Calcineurin Activates Nfat |
| Calcineurin Activates Nfat | POSITIVELY CORRELATED WITH | Inflammatory Response |
| Inflammatory Response | POSITIVELY CORRELATED WITH | Pyoderma Gangrenosum |
|---------|-----------|---------|

Reference: 
  - [https://go.drugbank.com/drugs/DB00845#BE0004716](https://go.drugbank.com/drugs/DB00845#BE0004716)
  - [https://pubmed.ncbi.nlm.nih.gov/22020137/](https://pubmed.ncbi.nlm.nih.gov/22020137/)
